Positive News SentimentPositive NewsNASDAQ:VINC Vincerx Pharma (VINC) Stock Forecast, Price & News $1.01 -0.03 (-2.88%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$0.98▼$1.0950-Day Range$0.66▼$1.2052-Week Range$0.63▼$1.95Volume176,966 shsAverage Volume93,193 shsMarket Capitalization$21.59 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Vincerx Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside296.0% Upside$4.00 Price TargetShort InterestHealthy1.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$26,030 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.85) to ($0.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.89 out of 5 starsMedical Sector52nd out of 973 stocksPharmaceutical Preparations Industry12th out of 449 stocks 3.5 Analyst's Opinion Consensus RatingVincerx Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Vincerx Pharma has a forecasted upside of 296.0% from its current price of $1.01.Amount of Analyst CoverageVincerx Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.31% of the float of Vincerx Pharma has been sold short.Short Interest Ratio / Days to CoverVincerx Pharma has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vincerx Pharma has recently decreased by 11.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVincerx Pharma does not currently pay a dividend.Dividend GrowthVincerx Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VINC. Previous Next 3.8 News and Social Media Coverage News SentimentVincerx Pharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vincerx Pharma this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added Vincerx Pharma to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vincerx Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $26,030.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.60% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.46% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Vincerx Pharma are expected to grow in the coming year, from ($1.85) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vincerx Pharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vincerx Pharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVincerx Pharma has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vincerx Pharma (NASDAQ:VINC) StockVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.Read More VINC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VINC Stock News HeadlinesSeptember 19, 2023 | finance.yahoo.comVincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023September 14, 2023 | finance.yahoo.comVincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943September 30, 2023 | Altimetry (Ad)Advisor to FBI: Sell META nowStocks just keep going up. But all isn’t what it seems, according to an FBI and Pentagon advisor. Find out what he knows, here.September 8, 2023 | benzinga.comDelveInsight Evaluates a Robust B-Cell Lymphoma Clinical Trial as 160+ Influential Pharma Companies to Set Foot in the 7MMAugust 23, 2023 | msn.comFDA approves Vincerx’s IND application for trial of VIP943August 23, 2023 | benzinga.comCancer Antibody Drug Conjugates Market Size Clinical Trials InsightAugust 23, 2023 | proactiveinvestors.comVincerx Pharma receives FDA clearance for early-stage leukemia trialAugust 22, 2023 | marketwatch.comVincerx Pharma Shares Jump 8% Premarket After FDA Clearance for Clinical TrialSeptember 30, 2023 | Altimetry (Ad)Advisor to FBI: Sell META nowStocks just keep going up. But all isn’t what it seems, according to an FBI and Pentagon advisor. Find out what he knows, here.August 10, 2023 | finance.yahoo.comVincerx Pharma (NASDAQ:VINC) Will Have To Spend Its Cash WiselyAugust 7, 2023 | finance.yahoo.comVincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateMay 23, 2023 | finance.yahoo.comRichter's Syndrome Pipeline Insight Report 2023: Featuring Secura Bio, Genmab, Genentech, Acerta Pharma & Vincerx PharmaMay 15, 2023 | markets.businessinsider.comVincerx Pharma Inc (VINC) Gets a Buy from SVB SecuritiesMay 12, 2023 | finanznachrichten.deVincerx Pharma, Inc.: Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | finance.yahoo.comVincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 19, 2023 | msn.comVincerx Pharma's Preclinical Data From Blood Cancer Candidate Shows Efficacy, Lower ToxicityApril 19, 2023 | finance.yahoo.comVincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual MeetingApril 17, 2023 | finance.yahoo.comVincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023April 17, 2023 | finance.yahoo.comVincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual MeetingMarch 30, 2023 | seekingalpha.comVINC Vincerx Pharma, Inc.March 28, 2023 | finance.yahoo.comVincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate UpdateFebruary 6, 2023 | finance.yahoo.comVincerx Pharma to Participate at the SVB Securities Global Biopharma ConferenceDecember 15, 2022 | msn.comPeering Into Vincerx Pharma's Recent Short InterestDecember 13, 2022 | finance.yahoo.comVincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236December 11, 2022 | finance.yahoo.comVincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022November 10, 2022 | finance.yahoo.comVincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateNovember 3, 2022 | finance.yahoo.comVincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022See More Headlines Receive VINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VINC Company Calendar Last Earnings8/07/2023Today9/29/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VINC CUSIPN/A CIK1796129 Webvincerapharma.com Phone650-800-6676FaxN/AEmployees41Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+296.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-134.99% Return on Assets-104.51% Debt Debt-to-Equity RatioN/A Current Ratio3.47 Quick Ratio3.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / Book0.45Miscellaneous Outstanding Shares21,380,000Free Float16,977,000Market Cap$21.59 million OptionableNot Optionable Beta0.41 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Ahmed M. Hamdy M.D. (Age 58)Founder, Chairman & CEO Comp: $609.84kDr. Raquel E. Izumi Ph.D. (Age 53)Founder, Pres, COO, Sec. & Director Comp: $551.66kMr. Alexander A. Seelenberger M.B.A. (Age 44)MBA, Chief Financial Officer Comp: $458.03kMr. Tom C. Thomas J.D. (Age 64)Founder, Gen. Counsel & Chief Legal Officer Dr. John C. Byrd M.D.Founder & Chairman of Scientific Advisory BoardDr. Hans-Georg Lerchen Ph.D.Chief Scientific OfficerMs. Gabriela JairalaSr Exec. Director of Investor Relations & Corp. CommunicationsMs. Karen QuarfordVP of Quality Operations & ComplianceMs. Melissa Merrick SPHRSr. Director of People & Culture and Head of Human ResourceDr. Beatrix Stelte-Ludwig Ph.D.Exec. Chief Devel. OfficerMore ExecutivesKey CompetitorsAcer TherapeuticsNASDAQ:ACERAcurx PharmaceuticalsNASDAQ:ACXPNRx PharmaceuticalsNASDAQ:NRXPPurple BiotechNASDAQ:PPBTCatalyst BiosciencesNASDAQ:CBIOView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCBought 36,595 shares on 8/15/2023Ownership: 3.089%Walleye Capital LLCBought 135,044 shares on 8/15/2023Ownership: 0.632%Schonfeld Strategic Advisors LLCSold 29,277 shares on 8/14/2023Ownership: 2.814%ExodusPoint Capital Management LPBought 34,724 shares on 8/11/2023Ownership: 1.995%Rubric Capital Management LPSold 32,342 shares on 8/11/2023Ownership: 1.658%View All Insider TransactionsView All Institutional Transactions VINC Stock - Frequently Asked Questions Should I buy or sell Vincerx Pharma stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VINC shares. View VINC analyst ratings or view top-rated stocks. What is Vincerx Pharma's stock price forecast for 2023? 2 Wall Street analysts have issued 12-month price objectives for Vincerx Pharma's stock. Their VINC share price forecasts range from $3.00 to $5.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 296.0% from the stock's current price. View analysts price targets for VINC or view top-rated stocks among Wall Street analysts. How have VINC shares performed in 2023? Vincerx Pharma's stock was trading at $1.02 at the start of the year. Since then, VINC stock has decreased by 1.0% and is now trading at $1.01. View the best growth stocks for 2023 here. When is Vincerx Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our VINC earnings forecast. How were Vincerx Pharma's earnings last quarter? Vincerx Pharma, Inc. (NASDAQ:VINC) released its quarterly earnings results on Monday, August, 7th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.13. What is Vincerx Pharma's stock symbol? Vincerx Pharma trades on the NASDAQ under the ticker symbol "VINC." How do I buy shares of Vincerx Pharma? Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vincerx Pharma's stock price today? One share of VINC stock can currently be purchased for approximately $1.01. How much money does Vincerx Pharma make? Vincerx Pharma (NASDAQ:VINC) has a market capitalization of $21.59 million. The company earns $-65,370,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. How can I contact Vincerx Pharma? Vincerx Pharma's mailing address is 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306. The official website for the company is vincerapharma.com. The company can be reached via phone at 650-800-6676. This page (NASDAQ:VINC) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.